SCHOTT Pharma AG & Co. KGaA SCHOTT Pharma AG & Co. KGaA

SCHOTT Pharma AG & Co. KGaA

1SXP

Rang in Aktien #3794
Globally, SCHOTT Pharma AG & Co. KGaA specializes in the development,... Globally, SCHOTT Pharma AG & Co. KGaA specializes in the development, manufacturing, and distribution of sophisticated containment and delivery systems specifically designed for injectable pharmaceuticals, catering to the needs of the pharmaceutical and biotechnology sectors. Their comprehensive product portfolio encompasses both polymer and glass options across various crucial categories, including syringes, ampoules, vials, and cartridges. Their extensive range of syringes features specialized solutions such as the syriQ series (including BioPure for biologics and silicone-free variants) crafted from glass, ideal for vaccines and sensitive biologics, alongside the versatile polymer-based SCHOTT TOPPAC line, tailored for applications from cosmetic treatments and deep-cold storage to infusion therapy and delicate drugs. For cartridges, SCHOTT Pharma provides the cartriQ pharmaceutical glass series, designed for peptide, protein, and large-volume injectables, as well as double-chamber options for lyophilized drugs and break-resistant variants, supplemented by their TopLine and StandardLine offerings. Vial solutions include the adaptiQ pharmaceutical glass vial for general injectables, the EVERIC range focused on drug stability (pure, care for pH, strong & smooth for filling lines), SCHOTT Type I plus for specific formulations, and TopLyo to prevent fogging in lyophilized drugs, alongside their TopLine and StandardLine vials. The ampoule selection features easyOPC for convenient opening, Anti-Counterfeiting ampoules for enhanced security, and their dependable StandardLine options. Established in 1884 and based in Mainz, Germany, SCHOTT Pharma AG & Co. KGaA functions as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.
Aktienkurs
$29.14
Marktkapitalisierung
$4.39B
Veränderung (1 Tag)
-4.77%
Veränderung (1 Jahr)
24.99%
Land
DE
Handel SCHOTT Pharma AG & Co. KGaA (1SXP)

Kategorie

Healthcare
Operative Marge für SCHOTT Pharma AG & Co. KGaA (1SXP)
Operative Marge zum 2026 TTM: 0.00%
Laut den neuesten Finanzberichten und dem Aktienkurs von SCHOTT Pharma AG & Co. KGaA beträgt die aktuelle operative Marge (TTM) 0.00%. Am Ende des Jahres 2026 lag die operative Marge bei 0.00%.
Historie der operativen Marge von SCHOTT Pharma AG & Co. KGaA von 2026 bis 2026
Operative Marge zum Jahresende
Jahr Operative Marge ändert
Nicht genügend Daten für die angegebenen Daten.
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Operative Marge Differenz der operativen Marge Land
Intuitive Surgical, Inc. Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
ISRG.US
31.28% -
US
EssilorLuxottica S.A. EssilorLuxottica S.A.
EssilorLuxottica S.A.
EL.PA
12.36% -
FR
HOYA Corporation HOYA Corporation
HOYA Corporation
7741.T
0.00% -
JP
Becton, Dickinson and Company Becton, Dickinson and Company
Becton, Dickinson and Company
BDX.US
9.83% -
US
Alcon Inc. Alcon Inc.
Alcon Inc.
ALC.SW
0.00% -
CH
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.